{"analyses":[{"ciLowerLimit":"0.531","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.949","estimateComment":"Stratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0199","paramType":"Hazard Ratio (HR)","paramValue":"0.710","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.00","upperLimit":"10.58","value":"8.51"},{"groupId":"OG001","lowerLimit":"5.42","upperLimit":"9.07","value":"7.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Best Supportive Care (BSC)"},{"description":"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.\n\nParticipants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Participants were censored in Ramucirumab arm = 50 and Placebo arm = 21. All randomized participants (including the censored participants) were included in the analyses.","reportingStatus":"POSTED","timeFrame":"From Date of Randomization to Death from Any Cause (Up to 28 Months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}